Network pharmacological studies revealed the relevant targets of GZFL136 potential bioactive components for the treatment of EMs, including IL-6, TP53, EGFR, ESR1 (ERα), PTGS2 (COX-2), and MMP9, and the potential mechanisms of action of these targets. The gene discussed is EGFR; the disease is eosinophilia-myalgia syndrome.